semaglutide anti aging A new study from UC San Diego offers early clinical evidence that semaglutide, a widely used GLP-1 receptor agonist, may slow biological aging. In a randomized, placebo-controlled trial, researchers observed a 9% Semaglutide Troche + B6 -

The broader peptide landscape offers other potential combination strategies as well

This means pyridoxine may provide proportionally greater benefit for semaglutide users than tirzepatide users, simply because the baseline nausea burden is higher

The researchers outlined potential mechanisms for GLP-1 receptor agonists, including anti-inflammatory effects, modulation of nociceptive signaling, and improved endothelial function with reduced arteriovenous shunting

Rainis T, Maor I, Lanir A, Shnizer S, Lavy A

Many people using GLP-1 medication describe renewed energy, steady progress on the scale, and a sense of hope

The H&E staining results (Fig